Bailey Webster 4

What Happened

• Bailey Webster, a director of Provectus Biopharmaceuticals, was granted 48,917 shares of Series D‑1 Convertible Preferred Stock on 2026-06-30. The award had $0 cash consideration and is reported as a derivative award on Form 4.
• Each Series D‑1 preferred share converts into 10 shares of Provectus common stock, so the award represents the potential to receive 489,170 common shares if converted. The Series D‑1 will automatically convert into common stock on December 31, 2028 (unless earlier converted per its terms).

Key Details

• Transaction date: 2026-06-30; Filing date/Period of Report: 2026-06-30 (timely filed).
• Instrument: Series D‑1 Convertible Preferred Stock; Transaction code: A (award/grant/acquisition).
• Award size: 48,917 preferred shares; conversion ratio: 1 preferred = 10 common; common-equivalent = 489,170 shares.
• Consideration paid: $0 (no cash paid by insider).
• Shares owned after transaction: Not disclosed in the Form 4 filing excerpt provided.
• Notable footnotes: F1 = 10:1 conversion ratio; F2 = automatic conversion date of 12/31/2028 (subject to Certificate of Designation terms).

Context

• This was an equity award of convertible preferred stock (a derivative), not an open‑market purchase or sale. Awards can be compensation or governance-related and do not by themselves indicate buying or selling sentiment.
• Upon conversion (automatic or voluntary), the preferred shares would dilute common shareholders by increasing the outstanding common share count (here, up to 489,170 potential common shares from this award).
• The filing does not state vesting conditions or whether conversion can occur earlier; consult the company’s Certificate of Designation or related filings for full terms.